ANAHEIM, Calif., April 18, 2011 /PRNewswire-FirstCall/ —
Questcor Pharmaceuticals, Inc. (NASDAQ:
QCOR) today announced that it will release first quarter 2011
financial results on Tuesday, April 26, 2011 after the close of the
U.S. financial markets. The Company will host a conference
call and webcast on Tuesday, April 26, 2011 at 4:30 p.m. Eastern /
1:30 p.m. Pacific to discuss results and highlights of the first
quarter, as well as current corporate developments.
Conference call details:Date:
Tuesday, April 26, 2011Time:
4:30 p.m. ETDial-in (U.S.):
877-941-1465Dial-in (International):
480-629-9678Web cast:
www.questcor.comTo access an
audio replay of the call:Replay (U.S.):
800-406-7325Replay (International):
303-590-3030Replay Passcode:
4434709About QuestcorQuestcor Pharmaceuticals, Inc. is a
biopharmaceutical company whose primary product helps patients with
serious, difficult-to-treat medical conditions. Questcor’s
primary product is H.P. Acthar® Gel (repository corticotropin
injection), an injectable drug that is approved by the FDA for the
treatment of 19 indications. Of these 19 indications,
Questcor currently generates substantially all of its net sales
from three indications: the treatment of acute exacerbations of
multiple sclerosis in adults, the treatment of infantile spasms in
children under two years of age and the treatment of nephrotic
syndrome. Specifically with respect to nephrotic syndrome, the FDA
has approved Acthar to “induce a diuresis or a remission of
proteinuria in the nephrotic syndrome without uremia of the
idiopathic type or that due to lupus erythematosus.” Questcor
is also exploring the possibility of developing markets for other
on-label indications and pursuing FDA approval of additional
indications not currently
‘/>”/>
